Wedbush Securities’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Wedbush Securities’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,330	Closed	-$6K	–	1140
2023 Q1	$6K	Sell	16,330 -1,970	-11%	-$1.77K	﹤0.01%	1075
2022 Q4	$16K	Hold	18,300	–	–	﹤0.01%	1040
2022 Q3	$29K	Hold	18,300	–	–	﹤0.01%	1026
2022 Q2	$37K	Hold	18,300	–	–	﹤0.01%	1045
2022 Q1	$43K	Buy	18,300 +300	+2%	+$936	﹤0.01%	1081
2021 Q4	$84K	Buy	18,000 +2,500	+16%	+$15.5K	﹤0.01%	1138
2021 Q3	$118K	Buy	15,500 +3,500	+29%	+$29.7K	0.01%	1119
2021 Q2	$116K	Buy	+12,000	New	+$95.6K	0.01%	1119
2021 Q1	–	Sell	-10,700	Closed	-$73K	–	1102
2020 Q4	$73K	Buy	+10,700	New	+$85.9K	0.01%	849

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

OAJ

Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

CFGS

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Wedbush Securities's SRNE Position: Q2 2023 in Review

Wedbush Securities sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 16,330 shares — an estimated $6K sold.

Wedbush Securities first reported a position in SRNE in Q4 2020 and held it in 9 quarters. The position peaked at $118K in Q3 2021. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

Wedbush Securities reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Wedbush Securities sold 16,330 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $6K.
Wedbush Securities first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 9 quarters.
Wedbush Securities's Sorrento Therapeutics, Inc. position peaked at $118K in Q3 2021.
9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Wedbush Securities's 13F filing for Q2 2023, filed 14 Aug 2023.